(Sharecast News) - Arecor Therapeutics announced on Monday that it has entered a formulation development partnership with Skye Bioscience to create an improved version of Skye's investigational obesity treatment, nimacimab.
The AIM-traded firm said the collaboration would apply its proprietary 'Arestat' technology to develop a higher-concentration formulation of the CB1-inhibiting monoclonal...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE